Ironwood Pharmaceuticals (IRWD) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

IRWD Ironwood Pharmaceuticals

Watchlist

5.830
-0.150-2.51%

Close Jun 14 16:00 ET

5.700
-0.130-2.23%

Post 16:42 ET

926.72MMarket Cap-866P/E (TTM)

Full Hours

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Insider Sale: Director Julie Mchugh Sells Shares of Ironwood Pharmaceuticals Inc (IRWD)
Yahoo FinanceJun 12 19:00 ET
Ironwood Pharmaceuticals(IRWD.US) Director Sells US$143.2K in Common Stock
$Ironwood Pharmaceuticals(IRWD.US)$ Director McHugh Julie sold 22,766 shares of common stock on Jun 10, 2024 at an average price of $6.29 for a total value of $143.2K.Source: Announcement What is stat
moomoo NewsJun 12 16:47 ET
Insider Sale: Director Catherine Moukheibir Sells 80,000 Shares of Ironwood Pharmaceuticals Inc ...
Yahoo FinanceJun 10 19:00 ET
Ironwood Pharmaceuticals(IRWD.US) Director Sells US$517.69K in Common Stock
$Ironwood Pharmaceuticals(IRWD.US)$ Director Moukheibir Catherine sold 80,000 shares of common stock on Jun 6, 7, 2024 at an average price of $6.47 for a total value of $517.69K.Source: Announcement W
moomoo NewsJun 10 17:44 ET
Form 144 | Ironwood Pharmaceuticals(IRWD.US) Director Proposes to Sell 144.56K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 10, $Ironwood Pharmaceuticals(IRWD.US)$ Director JULIE MCHUGH intends to sell 22,766 shares of its common stock on Jun 10, with a total market value of approximately $144.5
moomoo NewsJun 10 17:01 ET
Ironwood Pharmaceuticals Insider Sold Shares Worth $517,694, According to a Recent SEC Filing
Catherine Moukheibir, Director, on June 06, 2024, sold 80,000 shares in Ironwood Pharmaceuticals (IRWD) for $517,694. Following the Form 4 filing with the SEC, Moukheibir has control over a total of 4
MT NewswiresJun 10 17:00 ET

Comments

Meltyy

May 12 21:23

🎯 Ph 3 readouts in Q2 2024...

$United Therapeutics(UTHR.US)$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Liquidia(LQDA.US)$ Phase 3
$United Therapeutics(UTHR.US)$ Phase 3
$MorphoSys(MOR.US)$ Phase 3
$Immunocore(IMCR.US)$ Phase 3
$Crinetics(CRNX.US)$ Phase 3
$UroGen Pharma Ltd(URGN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$Capricor Therapeutics(CAPR.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3...

Luzi Ann Santos

Feb 29 10:54

ColumnsIronwood Pharma Shares Tank 40% as Drug Trial Misses Secondary Goal

$Ironwood Pharmaceuticals(IRWD.US)$ shares sank almost 40% after the drugmaker said its global phase III trial of Apraglutide, a treatment for short bowel syndrome, missed two of its four secondary goals.
That muddies the prospects for the company that's seeking to expand its product pipeline beyond Linzess.
Ironwood, which has been operating at a loss, sourced almost ll of its $117.6 million revenue in 2023 from its collaborati...

Meltyy

Feb 21 22:05

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q1 2024...
$Pfizer(PFE.US)$ Phase 3
$Palatin Technologies(PTN.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$ $Novocure(NVCR.US)$ Phase 3
$ROCHE HOLDING AG(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US)$ Phase 3
$Sellas Life Sciences(SLS.US)$...

Moomoo AI

Feb 18 08:16

Thomas McCourt's recent sale at the current share price of US$14.58 raises caution. More selling than buying by insiders over the past year and low insider ownership could concern potential investors.